KUALA LUMPUR, Sept 2 (Bernama) — Myriad Genetics Inc has announced Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study showing the EndoPredict® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer.
“This important publication on the new EndoPredict data demonstrates our ongoing commitment to advance precision medicine for patients with breast cancer,” said director of International Medical Affairs, Myriad Genetics, Dr Ralf Kronenwett.
According to a statement, this newly published study represents the first clinical validation of EndoPredict in a solely premenopausal population.
The study — first presented in an abstract at the 2021 ASCO Annual Meeting by Anastasia Constantinidou et al — examined tumour samples from 385 premenopausal women with ER+, HER2- primary breast cancer who had not received chemotherapy.
The results show EndoPredict accurately identified premenopausal women with and without affected lymph nodes who could safely avoid adjuvant chemotherapy as part of their treatment plans due to a very low recurrence risk.
The study shows that patients with EndoPredict low-risk scores had a 97 per cent distant recurrence free survival (DRFS) versus 76 per cent for high-risk patients.
Importantly, 19 per cent of node-positive premenopausal patients had EndoPredict low-risk scores with 100 per cent DRFS and were able to safely avoid chemotherapy and continue onto endocrine therapy alone.
Another key result from an exploratory subgroup analysis within the study found similar DRFS rates in low-risk patients with or without ovarian function suppression (OFS), with less than five per cent distant recurrence after 10 years in both groups.
Source: BERNAMA News Agency